In Canada, the prevalence of depression and mental health disorders has shown a worrying increase. According to data from 2022, over 5 million Canadians, accounting for 18% of the…
clinical trials
Breast cancer is the most diagnosed cancer among Canadian women and is the 2nd leading cause of cancer death. One in eight Canadian women can expect to receive a…
Cybin (CYBN.NEO), a Canadian-based biopharmaceutical company working to transform psychedelics into therapeutics, announced today that it had received approval from an independent ethics committee in the Netherlands to commence…
Filament Health (FH.E) inked a supply deal with Optimi Health (OPTI.C) for psilocybin mushrooms for testing and analysis by Filament’s research team. These mushrooms come at the behest of…
Sunshine Biopharma (SBFM) is definitely bringing some sunshine for its shareholders today. At the highest price of $6.80 today, which also is all time record highs, the stock was…
The COVID-19 pandemic and variant friends are almost securely in our rear-view for another year and soon the beaches will be full of people and the papers will be…
Tetra Bio-Pharma (TBP.T) received Health Canada’s approval for their amendment of a phase I study involving the safety profile of low and moderate doses of inhaled CBD. They’re conducting…
Standardizing Psychedelic-Assisted Therapy $25.537M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has entered into a licensing agreement with ATMA Journey Centers. Under the agreement, Filament has…
Problematic Psychedelics? Psychedelics and mental health treatment go together like orange juice and toothpaste. That’s what I would have said five years ago. Prior to the publication of multiple…
Filament Health (FH.NE) announced today that it has received approval from Health Canada for a Phase 2 clinical trial using PEX010, the Company’s botanical psilocybin drug candidate. Cybin Therapeutics…